Finally, in both FD mouse models and patients [29–33], tissue changes occur in FD lesions exposed to medical treatments, especially denosumab, a humanized monoclonal antibody neutralizing RANKL, which inhibits osteoclastogenesis and converts the fibrous tissue into hyper-mineralized bone. Here, TNFSF11 is linked to Fabry disease.